Your browser doesn't support javascript.
loading
Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Ito, Satoru; Otsuki, Sachie; Ohsawa, Hirokazu; Hirano, Atsushi; Kazuno, Hideki; Yamashita, Satoshi; Egami, Kosuke; Shibata, Yoshihiro; Yamamiya, Ikuo; Yamashita, Fumiaki; Kodama, Yasuo; Funabashi, Kaoru; Kazuno, Hiromi; Komori, Toshiharu; Suzuki, Satoshi; Sootome, Hiroshi; Hirai, Hiroshi; Sagara, Takeshi.
Afiliação
  • Ito S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Otsuki S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Ohsawa H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Hirano A; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Kazuno H; Formulation Research Lab, CMC Division, Taiho Pharmaceutical Co. Ltd., Tokushima, Tokushima 771-0194, Japan.
  • Yamashita S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Egami K; Intellectual Property Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan.
  • Shibata Y; MA Project Management Office, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan.
  • Yamamiya I; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Yamashita F; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Kodama Y; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Funabashi K; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Kazuno H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Komori T; Regulatory Affairs Department, Taiho Pharmaceutical Co. Ltd., 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan.
  • Suzuki S; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Sootome H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Hirai H; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
  • Sagara T; Discovery and Preclinical Research Division, Taiho Pharmaceutical Co. Ltd., Tsukuba, Ibaraki 300-2611, Japan.
ACS Med Chem Lett ; 14(4): 396-404, 2023 Apr 13.
Article em En | MEDLINE | ID: mdl-37077386
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article